Lixte Biotechnology Holdings, a clinical-stage pharmaceutical company based in East Setauket, New York, focuses on developing LB-100 series inhibitors for cancer and other life-threatening diseases since its IPO in 2007. The company’s lead compounds demonstrate anti-cancer activity in various human cancers, including glioblastoma multiforme and neuroblastoma.